{"id":"mycophenoate-mofetil","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Gastrointestinal disturbances (diarrhea, nausea, vomiting, abdominal pain)"},{"rate":"15-25","effect":"Leukopenia"},{"rate":"10-15","effect":"Anemia"},{"rate":"20-30","effect":"Infection"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Tremor"}]},"_chembl":{"chemblId":"CHEMBL1456","moleculeType":"Small molecule","molecularWeight":"433.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mycophenolate mofetil is a prodrug that is rapidly hydrolyzed to mycophenolic acid (MPA), which preferentially inhibits IMPDH type II, an enzyme critical for guanosine nucleotide synthesis in lymphocytes. By depleting guanosine nucleotides, MPA selectively suppresses T and B cell proliferation while having minimal effects on other cell types, making it an effective immunosuppressant for preventing organ transplant rejection and treating autoimmune conditions.","oneSentence":"Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent immune rejection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:20.742Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ transplant rejection (renal, cardiac, hepatic)"},{"name":"Active lupus nephritis"},{"name":"Autoimmune conditions requiring immunosuppression"}]},"trialDetails":[{"nctId":"NCT02686619","phase":"PHASE3","title":"Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-11","conditions":"Renal Transplantation","enrollment":237}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"COUGH"},{"count":1,"reaction":"DIABETIC KETOACIDOSIS"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"INSOMNIA"},{"count":1,"reaction":"LARYNGOSPASM"},{"count":1,"reaction":"MEMORY IMPAIRMENT"},{"count":1,"reaction":"NERVOUSNESS"},{"count":1,"reaction":"PSYCHOMOTOR HYPERACTIVITY"},{"count":1,"reaction":"SWOLLEN TONGUE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CellCept"],"phase":"phase_3","status":"active","brandName":"Mycophenoate Mofetil","genericName":"Mycophenoate Mofetil","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent immune rejection. Used for Prevention of organ transplant rejection (renal, cardiac, hepatic), Active lupus nephritis, Autoimmune conditions requiring immunosuppression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}